Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Heron Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Is hospitalized for ≤48 hours with SARS-CoV-2 infection. Confirmed by polymerase chain reaction (PCR), antigen or immunoglobulin M (IgM) antibody test.
Has at least 1 of the following: Radiographic infiltrates by imaging, or oxygen saturation of \<94% by pulse oximetry on room air or requiring supplemental oxygen.
Not anticipated to require mechanical ventilation within 48 hours.
You may not be if
Is taking high-dose hydroxychloroquine or chloroquine.
Is taking pimozide or strong or moderate CYP3A4 inhibitors.
Is currently receiving treatment with products intended to modify immune response to COVID-19 (exception: dexamethasone, methylprednisolone, or equivalent are allowed), chemotherapy or on hemodialysis or peritoneal dialysis.
Has known hypersensitivity to any components of aprepitant injectable emulsion.
Has evidence of ARDS.
Is being treated with oxygen delivered by high-flow nasal cannula nonrebreather mask, noninvasive positive pressure ventilation, or ECMO.
Has multiple organ failure.
Has current confirmed Influenza A or B infection, or a a history of organ or hematologic transplant, HIV, or active hepatitis B or hepatitis C infection.
Clareo Health | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
